BidaskClub cut shares of Entellus Medical (NASDAQ:ENTL) from a sell rating to a strong sell rating in a research report released on Saturday.
Several other brokerages also recently commented on ENTL. TheStreet raised Entellus Medical from a d rating to a c- rating in a research report on Thursday, December 14th. Zacks Investment Research downgraded Entellus Medical from a hold rating to a sell rating in a research report on Wednesday, January 24th. ValuEngine raised Entellus Medical from a sell rating to a hold rating in a research report on Thursday, December 7th. Finally, William Blair downgraded Entellus Medical from an outperform rating to a market perform rating in a research report on Friday, December 8th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $19.25.
Entellus Medical (NASDAQ ENTL) opened at $24.06 on Friday. The company has a market capitalization of $619.02, a price-to-earnings ratio of -18.65 and a beta of -0.02. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $25.58.
In other news, insider Robert S. White sold 3,471 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $24.01, for a total transaction of $83,338.71. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Brian E. Farley sold 101,319 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $23.85, for a total value of $2,416,458.15. The disclosure for this sale can be found here. Insiders sold a total of 108,942 shares of company stock worth $2,599,658 in the last ninety days. 7.70% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of ENTL. Metropolitan Life Insurance Co. NY bought a new position in shares of Entellus Medical during the 4th quarter worth $105,000. Nationwide Fund Advisors grew its position in shares of Entellus Medical by 61.7% during the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after buying an additional 2,635 shares in the last quarter. MetLife Investment Advisors LLC bought a new position in shares of Entellus Medical during the 4th quarter worth $152,000. JPMorgan Chase & Co. grew its position in shares of Entellus Medical by 145.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after buying an additional 5,605 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Entellus Medical by 61.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock worth $196,000 after buying an additional 4,533 shares in the last quarter. 83.44% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/20/bidaskclub-lowers-entellus-medical-entl-to-strong-sell-2.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.